How much funding has Biohaven Ltd. Common Shares raised?

Biohaven Ltd. Common Shares has raised $493.6M in total funding, most recently a Venture Round.

Who are Biohaven Ltd. Common Shares's investors?

Biohaven Ltd. Common Shares's investors include Oberland Capital, Sixth Street, Venrock, RA Capital Management, Vivo Capital, Aisling Capital.

When was Biohaven Ltd. Common Shares founded?

Biohaven Ltd. Common Shares was founded in 2013.

Where is Biohaven Ltd. Common Shares headquartered?

Biohaven Ltd. Common Shares is headquartered in New Haven, Connecticut, United States.

What industry is Biohaven Ltd. Common Shares in?

Biohaven Ltd. Common Shares operates in Biotech, Healthcare.

How many employees does Biohaven Ltd. Common Shares have?

Biohaven Ltd. Common Shares has 201-500 employees.

Biohaven Ltd. Common Shares

IPO

Clinical-stage Biopharmaceutical Company | Biohaven

Public · New Haven, United States · Founded 2013 · $493.6M raised

Biotech

Healthcare

Headquarters: New Haven, Connecticut
Employees: 201–500
Founded: 2013
Business Model: B2B
Website: biohaven.com

Total Funding: $493.6M
Last Round: $375.0M Venture RoundAug 2020
Rounds: 4
Type: Public

About

Biohaven is a clinical-stage biopharmaceutical company advancing a portfolio of more than 10 drug candidates across 6 therapeutic areas including neurology, immunology, oncology, and cardiometabolic disease. Its proprietary platforms — MoDE extracellular protein degraders, Kv7 potassium channel activators, and myostatin inhibitors — target rare and common diseases with unmet needs. Lead programs include BHV-8000 for Parkinson's disease and Alzheimer's, opakalim (BHV-7000) for epilepsy, and taldefgrobep alfa for spinal muscular atrophy and obesity.

Summary

Biohaven Ltd. Common Shares is a Biotech company based in New Haven, United States, founded in 2013. It has raised $493.6M in total across 4 rounds, most recently a $375.0M Venture Round round in Aug 2020. Investors include Oberland Capital, Sixth Street and Venrock.

LinkedIn X (Twitter)